Showing 5511-5520 of 8839 results for "".
- Hoth Therapeutics Gets Greenlight to Start Phase 1b Trial of BioLexa for AD in Australiahttps://practicaldermatology.com/news/hoth-therapeutics-gets-greenlight-to-start-phase-1b-trial-of-biolexa-for-ad-in-australia/2460627/Hoth Therapeutics, Inc. received Human Research Ethics Committee clearance to commence the first cohort of the Phase 1b clinical trial of
- Telemedicine Slashes Dermatology Consult Time from 84 Days to 5 Hourshttps://practicaldermatology.com/news/telemedicine-slashes-dermatology-consult-time-from-84-days-to-5-hours/2460609/When patients’ primary care doctors were able to photograph areas of concern and share them with dermatologists, the response time for a consultation dropped from almost 84 days to under five hours, finds a new study from researchers in the Perelman School of Medicine at the Unive
- Avita Therapeutics, Houston Methodist Research Institute to Develop New Ways to Rejuvenate Aging Skinhttps://practicaldermatology.com/news/avita-therapeutics-houston-methodist-research-institute-to-develop-new-ways-to-rejuvenate-aging-skin/2460608/Avita Therapeutics’ is partnering with Houston Methodist Research Institute (HMRI) to identify novel approaches to reverse skin aging and rejuvenate skin with the potential for broader applicability such as scar revision and wound healing. The project seeks to establish
- New from Lutronic: Accufit for Muscle Stimulationhttps://practicaldermatology.com/news/new-from-lutronic-accufit-for-muscle-stimulation/2460599/Lutronic is launching Accufit, a new device for targeted muscle activation. Eight IntelliSTIM electrodes distribute energy and generate strong muscular contractions on any area needed to be treated without pain or skin sensitivity. Accufit's IntelliPhase waveforms produce four
- Safety and Tolerability Update for LEO's Tralokinumabhttps://practicaldermatology.com/news/safety-and-tolerability-update-for-leos-tralokinumab-1/2460590/LEO Pharma’s tralokinumab is well tolerated when used as monotherapy or in combination therapy with the topical corticosteroid (TCS) mometasone furoate, according to a late-breaking data analysis presented online at European Academy of Dermatology and Ve
- Dermatologist Named AAD Patient Hero for Providing Skin Care to People Experiencing Homelessness Amid COVID-19https://practicaldermatology.com/news/dermatologist-names-aad-patient-hero-for-providing-skin-care-to-people-experiencing-homelessness-amid-covid-19/2460582/Jennifer Tan, MD, FAAD is an American Academy of Dermatology (AAD) Patient Care Hero for making critical skin care and hygiene items easily accessible to individuals experiencing homelessness during the COVID-19 pandemic. As the state government issued COVID-19 stay-at-home guidanc
- Arcutis: Phase 1/2b Enrollment Complete for ARQ-252 in Chronic Hand Eczemahttps://practicaldermatology.com/news/arcutis-phase-12b-enrollment-complete-for-arq-252-in-chronic-hand-eczema/2460578/Arcutis Biotherapeutics, Inc. has completed enrollment in the Phase 1/2b studyof its Janus kinase type 1(JAK1) ARQ-252 in adult patients with chronic hand eczema. Arcutis has updated its projected topline data from this trial to mid-2021.
- DermOQ To Buy Skin Products's ECHO2 Plus Oxygen Facial Treatment Product Linehttps://practicaldermatology.com/news/dermoq-to-buy-skin-products-incs-echo2-plus-oxygen-facial-treatment-product-line/2460569/DermOQ Inc. is purchasing Skin Products Inc.’s ECHO2 Plus and Oxyceuticals oxygen facial treatment product lines. DermOQ offers its topical oxygen products under the brand names DermOQ Oxygen Lab and
- Optical Coherence Tomography Plus AI Can Quickly and Accurately Monitor Hair Regrowthhttps://practicaldermatology.com/news/optical-coherence-tomography-plus-ai-can-quickly-and-accurately-monitor-hair-regrowth/2460564/Optical coherence tomography plus artificial intelligence methods can accurately and efficiently monitor hair growth therapies, suggests a
- EB Research Partnership and EB Research Foundation Form Largest Global Organization Advancing EB Researchhttps://practicaldermatology.com/news/eb-research-partnership-and-eb-research-foundation-form-largest-global-organization-advancing-eb-research/2460559/EB Research Partnership (EBRP), based in New York, and EB Research Foundation (EBRF) of Australia are uniting to become the largest global organization focused on funding research to discover treatments and cures for Epidermolysis Bullosa (EB). As the two leading organiza